A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial To Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy in Essential Hypertension Subjects Inadequately Controlled by D064 Monotherapy

NCT05526703 Phase 3 UNKNOWN

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy.

Details

Lead sponsor	Chong Kun Dang Pharmaceutical
Phase	Phase 3
Status	UNKNOWN
Enrolment	108
Start date	2022-09-28
Completion	2023-10

Conditions

• Essential Hypertension

Interventions

• D064, D701, placebo of D012
• D012, placebo of D064, placebo of D701

Primary outcomes

• Change from baseline in MSSBP — 8 weeks after drug administrations
  Compare experimental group with comparator group

Countries

South Korea